Braun Stacey Invests $16.7M in Insulet; Q3 EPS Beats by $0.11, Price Targets Raised
Braun Stacey Associates added 53,952 Insulet shares valued at $16.7 million in Q3, while Vanguard, Geode and Federated Hermes raised stakes by 0.5%, 3.1% and 14.3%, respectively. Insulet posted Q3 EPS of $1.24, beating estimates by $0.11 despite $521.7 million revenue falling short, and analysts lifted targets up to $415.
1. Omnipod 5 Adoption Accelerates and Margins Expand
Insulet reported that installations of its Omnipod 5 automated insulin delivery system grew 45% sequentially in the third quarter, reaching over 90,000 active users globally. The company achieved a gross margin of 67.5% for the quarter, up from 64.2% in Q2, driven by higher production volumes at its Bedford, Massachusetts manufacturing facility and improved supply chain efficiency. Management reiterated its target of 70% gross margin by year-end, citing ramped pod assembly automation and reduced component costs as key drivers.
2. Institutional Investors Increase Exposure
During the third quarter, Braun Stacey Associates acquired 53,952 shares of Insulet, representing a $16.7 million commitment and a 0.08% stake in the business. Meanwhile, Vanguard Group boosted its holdings by 39,403 shares to a total of 8.71 million, Geode Capital added 58,309 shares taking its position to 1.93 million, and Federated Hermes increased its stake by 14.3% to 723,363 shares. Norges Bank initiated a new position valued at $324.7 million, underscoring growing confidence among large asset managers in Insulet’s long-term growth trajectory.
3. Q3 Financial Results Exceed Expectations
For the quarter ended September 30, Insulet reported revenue of $522 million, up 30% year-over-year, and adjusted EPS of $1.24, beating consensus estimates by $0.11. Net margin widened to 9.8% from 8.4% in the prior year period, reflecting operating leverage as R&D and SG&A expenses grew at a slower pace than sales. Free cash flow reached $95 million, up from $60 million a year earlier, driven by strong working capital management and higher profit contributions from consumable pods.
4. Analyst Ratings and Price Targets Revised Upward
Analysts have lifted their outlooks following Insulet’s quarterly report. JPMorgan raised its target by 22% to $415, citing accelerating pod adoption and margin expansion, while Raymond James upped its objective to $385 and reaffirmed an ‘outperform’ stance based on robust international rollout prospects. Wolfe Research, Rothschild & Co Redburn and Leerink Partners similarly raised their targets into the $370–386 range, reflecting an average expected total return above 25% over the next 12 months.